NMDA Suppresses Pancreatic ABCA1 Expression through the MEK/ERK/LXR Pathway in Pancreatic Beta Cells
Nutrients · 2024
DOI: 10.3390/nu16172865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Takanobu Saheki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun 761-0793, Japan. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, ATP Binding Cassette Transporter 1, N-Methylaspartate, Liver X Receptors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.
Abstract (Originalsprache)
Dysfunction or loss of pancreatic β cells can cause insulin deficiency and impaired glucose regulation, resulting in conditions like type 2 diabetes. The ATP-binding cassette transporter A1 (ABCA1) plays a key role in the reverse cholesterol transport system, and its decreased expression is associated with pancreatic β cell lipotoxicity, resulting in abnormal insulin synthesis and secretion. Increased glutamate release can cause glucotoxicity in β cells, though the detailed mechanisms remain unclear. This study investigated the effect of N-methyl-D-aspartic acid (NMDA) on ABCA1 expression in INS-1 cells and primary pancreatic islets to elucidate the signaling mechanisms that suppress insulin secretion. Using Western blotting, microscopy, and biochemical analyses, we found that NMDA activated the mitogen-activated protein kinase (MEK)-dependent pathway, suppressing ABCA1 protein and mRNA expression. The MEK-specific inhibitor PD98059 restored ABCA1 promoter activity, indicating the involvement of the extracellular signal-regulated kinase (MEK/ERK) pathway. Furthermore, we identified the liver X receptor (LXR) as an effector transcription factor in NMDA regulation of ABCA1 transcription. NMDA treatment increased cholesterol and triglyceride levels while decreasing insulin secretion, even under high-glucose conditions. These effects were abrogated by treatment with PD98059. This study reveals that NMDA suppresses ABCA1 expression via the MEK/ERK/LXR pathway, providing new insights into the pathological suppression of insulin secretion in pancreatic β cells and emphasizing the importance of investigating the role of NMDA in β cell dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun 761-0793, Japan.
ORCID-Profile: Takanobu Saheki, Kensaku Fukunaga, Koji Murao
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI
Zitieren
APA
Saheki, T., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Yoshimura, T., Saheki, N., & Murao, K. (2024). NMDA Suppresses Pancreatic ABCA1 Expression through the MEK/ERK/LXR Pathway in Pancreatic Beta Cells. Nutrients. https://doi.org/10.3390/nu16172865
Vancouver
Saheki T, Imachi H, Fukunaga K, Sato S, Kobayashi T, Yoshimura T, et al. NMDA Suppresses Pancreatic ABCA1 Expression through the MEK/ERK/LXR Pathway in Pancreatic Beta Cells. Nutrients. 2024. doi:10.3390/nu16172865
BibTeX
@article{Saheki2024,
author = {Saheki, Takanobu and Imachi, Hitomi and Fukunaga, Kensaku and Sato, Seisuke and Kobayashi, Toshihiro and Yoshimura, Takafumi and Saheki, Nao and Murao, Koji},
title = {NMDA Suppresses Pancreatic ABCA1 Expression through the MEK/ERK/LXR Pathway in Pancreatic Beta Cells},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16172865}
}
EUVIMED